Correction to ‘Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective’
Ali NH, Al-Kuraishy HM, Al-Gareeb AI, et al. Neprilysin inhibitors and risk of Alzheimer's disease: a future perspective. J Cell Mol Med. 2024;28:e17993. doi:10.1111/jcmm.17993
In Introduction section, the sentence ‘AD is the most common type of dementia, accounting for about 70% of all dementia types’.1 is incorrect. The sentence should have read: ‘AD is the most common type of dementia, accounting for about 60% to 80% of all dementia types’.1,149
In Introduction section, the sentence ‘AD is the seventh leading cause of death in the United States, affecting 50 million people globally.3 Approximately 6% of the general population is affected, whereas more than 65% of affected cases are women; nonetheless, 10% of early-onset dementia affecting people aged 30–60 is attributed to AD’.3 is incorrect. The sentence should have read: ‘The global incidence of all-cause dementia is projected to rise from 50 million in 2010 to 113 million by 2050.3 Currently, over 55 million people suffer from AD, which ranks as the seventh leading cause of death in the United States.150 Additionally, women constitute over 65% of those affected by AD in the United States.151 Nonetheless, 10% of early-onset dementia affecting people aged 30–60 is attributed to AD’.3
In the section 3 NEP INHIBITORS IN AD, the sentence ‘Sacubitril was the first NEP inhibitor approved in 2015 to manage heart failure’.40 is incorrect. The sentence should have read: ‘Sacubitril was the first NEP inhibitor approved in 2015 to manage heart failure’.40,152
Finally in Table 2 for the Bavishi et al.43 the study type ‘Experimental study’ is incorrect. The correct is ‘Review’.
New References
(149) (2023), 2023 Alzheimer's disease facts and figures. Alzheimer's Dement. 19: 1598-1695. doi:10.1002/alz.13016
(150) 2024 Alzheimer's disease facts and figures. 1/6/2024. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf
(151) Rabinovici GD. Late-onset Alzheimer Disease. Continuum (Minneap Minn). 2019;25(1):14-33. doi: 10.1212/CON.0000000000000700. PMID: 30707185; PMCID: PMC6548536.
(152) Fala L. Entresto (Sacubitril/Valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure. Am Health Drug Benefits. 2015;8(6):330-334. PMID: 26557227; PMCID: PMC4636283.
We apologize for this error.
